Press Releases Akzo Nobel developing human H5N1 vaccine
Nobilon International in conjunction with Organon is developing a human vaccine against the deadly H5N1 strain of the avian flu virus.  Akzo Nobel developing human H5N1 vaccine
Press release October 2005, pdf file (60Kb)
Nobilon receives European GMP approval
This means that Nobilon is now licensed to manufacture flu vaccines to be used in clinical testing, with the first trials scheduled to start in 2006.Nobilon receives European GMP approval for production of Influenza vaccines for clinical trials
Press release October 2005, pdf file (96Kb) Akzo Nobel’s Nobilon and BioDiem sign influenza vaccine tie-up
Nobilon International announces that it has entered into a licensing agreement with Australian pharmaceutical development company BioDiem Ltd.
Akzo Nobel’s Nobilon and BioDiem sign influenza vaccine tie-up
Press release November 2004, pdf file (102Kb)
| 
